Literature DB >> 17391701

Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.

Sharareh Emadi1, Hedieh Barkhordarian, Min S Wang, Philip Schulz, Michael R Sierks.   

Abstract

Protein misfolding and aggregation are pathological aspects of numerous neurodegenerative diseases. Aggregates of alpha-synuclein are major components of the Lewy bodies and Lewy neurites associated with Parkinson's Disease (PD). A natively unfolded protein, alpha-synuclein can adopt different aggregated morphologies, including oligomers, protofibrils and fibrils. The small oligomeric aggregates have been shown to be particularly toxic. Antibodies that neutralize the neurotoxic aggregates without interfering with beneficial functions of monomeric alpha-synuclein can be useful therapeutics. We were able to isolate single chain antibody fragments (scFvs) from a phage displayed antibody library against the target antigen morphology using a novel biopanning technique that utilizes atomic force microscopy (AFM) to image and immobilize specific morphologies of alpha-synuclein. The scFv described here binds only to an oligomeric form of alpha-synuclein and inhibits both aggregation and toxicity of alpha-synuclein in vitro. This scFv can have potential therapeutic value in controlling misfolding and aggregation of alpha-synuclein in vivo when expressed intracellularly in dopaminergic neurons as an intrabody.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391701      PMCID: PMC2235820          DOI: 10.1016/j.jmb.2007.02.089

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  66 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

2.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.

Authors:  L C Serpell; J Berriman; R Jakes; M Goedert; R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

3.  A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

Authors:  B I Giasson; I V Murray; J Q Trojanowski; V M Lee
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

4.  Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein.

Authors:  T Takenouchi; M Hashimoto; L J Hsu; B Mackowski; E Rockenstein; M Mallory; E Masliah
Journal:  Mol Cell Neurosci       Date:  2001-01       Impact factor: 4.314

5.  Monoclonal antibodies that target pathological assemblies of Abeta.

Authors:  Mary P Lambert; Pauline T Velasco; Lei Chang; Kirsten L Viola; Sara Fernandez; Pascale N Lacor; Daliya Khuon; Yuesong Gong; Eileen H Bigio; Pamela Shaw; Fernanda G De Felice; Grant A Krafft; William L Klein
Journal:  J Neurochem       Date:  2006-11-20       Impact factor: 5.372

6.  A Drosophila model of Parkinson's disease.

Authors:  M B Feany; W W Bender
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

7.  Conformation-dependent anti-amyloid oligomer antibodies.

Authors:  Rakez Kayed; Charles G Glabe
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

8.  Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies.

Authors:  Hedieh Barkhordarian; Sharareh Emadi; Philip Schulz; Michael R Sierks
Journal:  Protein Eng Des Sel       Date:  2006-09-19       Impact factor: 1.650

9.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Authors:  E Masliah; E Rockenstein; I Veinbergs; M Mallory; M Hashimoto; A Takeda; Y Sagara; A Sisk; L Mucke
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

10.  alpha-Synuclein membrane interactions and lipid specificity.

Authors:  E Jo; J McLaurin; C M Yip; P St George-Hyslop; P E Fraser
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

View more
  62 in total

1.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 2.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

3.  Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy.

Authors:  Warren D Marcus; Hongda Wang; Stuart M Lindsay; Michael R Sierks
Journal:  Nanomedicine       Date:  2008-01-16       Impact factor: 5.307

Review 4.  Progress in phage display: evolution of the technique and its application.

Authors:  Tomaz Bratkovic
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

Review 5.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 6.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

7.  Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Authors:  Sharareh Emadi; Srinath Kasturirangan; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

Review 8.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Authors:  Erik Kvam; Brent L Nannenga; Min S Wang; Zongjian Jia; Michael R Sierks; Anne Messer
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.

Authors:  Min S Wang; Shanta Boddapati; Sharareh Emadi; Michael R Sierks
Journal:  BMC Neurosci       Date:  2010-04-30       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.